Exciting new findings in prostate cancer research were reported by Xinning Wang and team at Case Western University, Comprehensive Cancer Center. Prostate cancer is the most common cancer among men and despite typically good prognosis, is a leading cause of cancer-related death. In the new study, the team combined chemotherapy with a novel light-activated, theranostic agent to enable targeted imaging and treatment of prostate cancer. Using ML7710 laser at 672 nm for activation of the drug, they were able to dramatically improve therapeutic effect in prostate cancer models with superior survival compared to either treatment modality alone. Because prostate cancer touches older people and with aging population, it creates a pressing public health concern where new treatment solutions are more needed than ever.

Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!

Modulight products used:

ML7710 – a clinical laser platform »

Read more:

In-vitro and in-vivo illumination »

About Modulight’s LASER-SHARP RESEARCH concept:

Laser-Sharp Research is a concept where our scientific board highlights cutting-edge scientific research articles from our customers. Important selection criteria are that Modulight and laser product are mentioned in the publication, the impact and relevance of the results, clinical translatability, as well as scientific quality of the journal. The nominated research groups will be rewarded to encourage the great work done.